Screener
ImmunityBio, Inc. IBRX Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SecuredLongTermDebt.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Due to related parties | 930 | 403 |
| Total current liabilities | 67,952 | 61,754 |
| Related-party convertible note payable, at fair value (Note 14) | 678,386 | 477,093 |
| Revenue interest liability (Note 13) | 404,299 | 324,615 |
| Operating lease liabilities, less current portion | 20,062 | 19,732 |
| Operating lease liabilities, less current portion – related parties | 13,085 | 13,715 |
| Derivative liabilities (Note 13) | 23,314 | 19,722 |
| Warrant liabilities (Note 16) | 308,193 | 84,417 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s long-term debt?
- ImmunityBio, Inc. (IBRX) reported long-term debt of $404.3M in Q1 2026.
- How has ImmunityBio, Inc.'s long-term debt changed year-over-year?
- ImmunityBio, Inc.'s long-term debt increased by 36.5% year-over-year, from $296.29M to $404.3M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about ImmunityBio, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude